Skip to main content

Booth Bruce's Form 4 filing

Kymera Therapeutics, Inc.KYMR · filed Apr 24, 2026

Accession no.
0001451612-26-000006
Filed
Apr 24, 2026
Trade date
Apr 22, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $539.8K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Booth BruceCIK 0001451612Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 22, 2026Common StockMOption exerciseAcquired+5,641$14.18+$79,989.385,641Direct
Apr 22, 2026Common StockMOption exerciseAcquired+259$20.00+$5,1805,900Direct
Apr 22, 2026Common StockSSaleDisposed−5,900$89.96F2−$530,7640Direct
Apr 22, 2026Common StockSSaleDisposed−88$90.08−$7,927.043,899,829Indirect
Apr 22, 2026Common StockSSaleDisposed−12$90.08−$1,080.96674,944Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 22, 2026Common StockMOption exerciseDisposed−5,641$0.00$00Direct
Apr 22, 2026Common StockMOption exerciseDisposed−259$0.00$039,868Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.95 to $90.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)